Mesoblast Limited (NASDAQ:MESO) saw unusually large options trading on Monday. Traders bought 6,669 call options on the company. This is an increase of approximately 1,144% compared to the average daily volume of 536 call options.
Shares of MESO opened at $7.41 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $961.37 million, a price-to-earnings ratio of -8.42 and a beta of 3.71. The stock has a 50 day moving average of $8.58 and a 200 day moving average of $10.39. Mesoblast has a 12 month low of $7.18 and a 12 month high of $21.28.
Mesoblast (NASDAQ:MESO) last released its earnings results on Tuesday, March 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.12). Mesoblast had a negative return on equity of 18.69% and a negative net margin of 591.00%. The firm had revenue of $2.24 million during the quarter, compared to analysts’ expectations of $2.14 million. As a group, equities research analysts predict that Mesoblast will post -0.63 earnings per share for the current year.
A number of research firms have recently commented on MESO. Maxim Group raised Mesoblast from a “hold” rating to a “buy” rating in a report on Tuesday, April 13th. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research report on Tuesday, January 19th. Finally, Zacks Investment Research upgraded Mesoblast from a “sell” rating to a “hold” rating in a research report on Thursday, March 4th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. Mesoblast presently has a consensus rating of “Hold” and a consensus target price of $15.79.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells.
Recommended Story: Non-Fungible Token (NFT)
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.